IDO inhibitors

US9765018B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Syngene International Limited · IN

Inventors

• Jay A. Markwalder · New London, US
• Steven P. Seitz · Swarthmore, US
• James Aaron Balog · Lambertville, US
• Audris Huang · Princeton, US
• Sunil Kumar Mandal · Bengaluru, IN
• David K. Williams · Cinnaminson, US
• Amy C. Hart · Ewing, US
• Jennifer Inghrim · Plainsboro, US

Key dates

• Filing date: Jul 1, 2014
• Grant date: Sep 19, 2017
• Expiry date: Jul 1, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.